OrbiMed’s Vaxcyte PCVX Stock Holding History

OrbiMed’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-250,000	Closed	-$6K	–	129
2022 Q3	$6K	Buy	+250,000	New	+$6.34M	0.11%	101

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

OrbiMed's PCVX Position: Q4 2024 in Review

OrbiMed sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 387,000 shares — an estimated $44.2M sold.

OrbiMed first reported a position in PCVX in Q2 2020 and held it in 18 quarters. The position peaked at $72.8M in Q1 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

OrbiMed reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
OrbiMed sold 387,000 Vaxcyte shares in Q4 2024, an estimated $44.2M.
OrbiMed first reported a position in Vaxcyte in Q2 2020 and held it in 18 quarters.
OrbiMed's Vaxcyte position peaked at $72.8M in Q1 2024.
323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on OrbiMed's 13F filing for Q4 2024, filed 14 Feb 2025.